Literature DB >> 11044558

The immunogenicity and efficacy of replication-defective and replication-competent bovine adenovirus-3 expressing bovine herpesvirus-1 glycoprotein gD in cattle.

P S Reddy1, N Idamakanti, C Pyne, A N Zakhartchouk, D L Godson, Z Papp, M E Baca-Estrada, L A Babiuk, G K Mutwiri, S K Tikoo.   

Abstract

Replication-competent and replication-defective bovine adenovirus type 3 recombinants expressing the bovine herpesvirus type 1 (BHV-1) glycoprotein D (gD) were tested for induction of gD specific immune responses in calves using intratracheal (1st and 2nd immunization) and sub-cutaneous (3rd immunization) route of immunization. The replication-defective recombinant BAV501 induced systemic immune responses against gD as low titers of anti gD-IgG were detected in the serum. However, the efficacy of the replication-competent BAV3.E3gD to induce gD-specific antibodies in the serum and the nasal secretions was superior to that of replication-defective BAV501 when both viruses were given at the same dosage. Partial protection from challenge was induced in calves immunized with replication-competent BAV3.E3gD. A dramatic increase in the titers of anti-gD IgG and IgA levels, both in serum and nasal secretions, following BHV-1 challenge (anamnestic response) suggested that the animals immunized with replication-defective BAV501 had been primed for gD-specific antibody responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044558     DOI: 10.1016/s0165-2427(00)00217-8

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  10 in total

1.  Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3.

Authors:  Dinesh S Bangari; Anurag Sharma; Suresh K Mittal
Journal:  Biochem Biophys Res Commun       Date:  2005-06-17       Impact factor: 3.575

2.  Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4-based vaccine vector development.

Authors:  Gaetano Donofrio; Valentina Franceschi; Antonio Capocefalo; Simone Taddei; Chiara Sartori; Sabrina Bonomini; Sandro Cavirani; Clotilde S Cabassi; Cesidio F Flammini
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

3.  Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1.

Authors:  Sunil K Khattar; Peter L Collins; Siba K Samal
Journal:  Vaccine       Date:  2010-02-26       Impact factor: 3.641

Review 4.  Development of nonhuman adenoviruses as vaccine vectors.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Vaccine       Date:  2005-09-23       Impact factor: 3.641

Review 5.  Bovine herpesvirus glycoprotein D: a review of its structural characteristics and applications in vaccinology.

Authors:  Luana Alves Dummer; Fábio Pereira Leivas Leite; Sylvia van Drunen Littel-van den Hurk
Journal:  Vet Res       Date:  2014-10-31       Impact factor: 3.683

Review 6.  Use of adenoviral vectors as veterinary vaccines.

Authors:  T B Ferreira; P M Alves; J G Aunins; M J T Carrondo
Journal:  Gene Ther       Date:  2005-10       Impact factor: 5.250

7.  Bovine Adenovirus-3 Tropism for Bovine Leukocyte Sub-Populations.

Authors:  Sugandhika Khosa; Maria Bravo Araya; Philip Griebel; Natasa Arsic; Suresh K Tikoo
Journal:  Viruses       Date:  2020-12-12       Impact factor: 5.048

8.  Clinical protection of goats against CpHV-1 induced genital disease with a BoHV-4-based vector expressing CpHV-1 gD.

Authors:  Gaetano Donofrio; Valentina Franceschi; Angela Lovero; Antonio Capocefalo; Michele Camero; Michele Losurdo; Sandro Cavirani; Mariarosaria Marinaro; Erika Grandolfo; Canio Buonavoglia; Maria Tempesta
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

Review 9.  Bovine adenovirus-3 as a vaccine delivery vehicle.

Authors:  Lisanework E Ayalew; Pankaj Kumar; Amit Gaba; Niraj Makadiya; Suresh K Tikoo
Journal:  Vaccine       Date:  2014-12-09       Impact factor: 3.641

10.  Development of a BoHV-4 viral vector expressing tgD of BoHV-1 and evaluation of its immunogenicity in mouse model.

Authors:  Seval Bilge-Dagalp; Touraj Aligholipour Farzani; Firat Dogan; Zeynep Akkutay Yoldar; Aykut Ozkul; Feray Alkan; Gaetano Donofrio
Journal:  Braz J Microbiol       Date:  2021-07-13       Impact factor: 2.476

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.